American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
American Journal of Medical Case Reports. 2019, 7(10), 253-259
DOI: 10.12691/ajmcr-7-10-8
Open AccessCase Report

A Fatal Case of Prochlorperazine-Induced Neuroleptic Malignant Syndrome: A Case Report and Literature Review

Tariq Sharman1,

1Department of Medicine, Heritage College of Osteopathic Medicine, Southern Ohio Medical Center, Ohio University, Portsmouth, Ohio, USA

Pub. Date: August 06, 2019

Cite this paper:
Tariq Sharman. A Fatal Case of Prochlorperazine-Induced Neuroleptic Malignant Syndrome: A Case Report and Literature Review. American Journal of Medical Case Reports. 2019; 7(10):253-259. doi: 10.12691/ajmcr-7-10-8


Neuroleptic malignant syndrome (NMS) is a medical emergency associated with the use of neuroleptics and antiemetics. NMS is characterized by a distinctive clinical syndrome of altered mental status, rigidity, hyperthermia, and autonomic dysfunction. NMS occurs as a result of changes in presynaptic or postsynaptic dopamine signaling. Central D2 receptor blockade in the hypothalamus, nigrostriatal pathways, and spinal cord leads to increased muscular rigidity and tremor via extrapyramidal pathways. Hypothalamic D2 receptor blockade results in an elevated temperature set point and impairment of heat-dissipating mechanisms. The reported mortality rates for NMS vary between 5 to 20 percent and the occurrence of medical complications and disease severity are the strongest predictors of mortality. This is a case of a 51 year old Caucasian female who presented with altered mental status, temperature of 109¡ãF, diffuse muscular rigidity and autonomic dysfunction manifested as labile blood pressure, tachypnea, hypoxemia and tachycardia after consuming 18 tablets of Prochlorperazine over three days for gastrointestinal upset. Her clinical presentation and laboratory work up were consistent with NMS and she developed fatal complications and multi-organ dysfunction secondary to Prochlorperazine-induced neuroleptic malignant syndrome.

neuroleptic malignant syndrome serotonin syndrome lethal catatonia malignant hyperthermia cholinergic crisis rigidity dysautonomia dantrolene bromocriptine amantadine creatine kinase prochlorperazine antipsychotic antiemetic seizure dopamine d2 receptor dystonia dyskinesia benzodiazepines electroconvulsive therapy ect hypothalamic extrapyramidal

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Delay J., Pichot P., Lemperiere T., Elissalde B., Peigne F. non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann. Med. Psychol. (Paris) 1960; 118(1): 145-152.
[2]  Gelenberg AJ; Bellinghausen B; Wojcik JD; Falk WE; Sachs GS. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry. 1988; 145(4): 517-8.
[3]  Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989; 50(1): 18.
[4]  Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality. Neurocrit Care. 2016; 24(1): 97.
[5]  Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993; 77(1): 185.
[6]  Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?. Neurology. 1981; 31(2): 132.
[7]  Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000; 85(1): 129.
[8]  Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia?. Clin Neuropharmacol. 2002; 25(4): 183.
[9]  Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Mov Disord. 1996; 11(6):726-8.
[10]  Keyser DL, Rodnitzky RL (1991). "Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy". Archives of Internal Medicine. 151(4): 794-6.
[11]  Strawn JR, Keck PE, Caroff SN (2007). "Neuroleptic malignant syndrome". The American Journal of Psychiatry. 164 (6): 870-6.
[12]  Otani K; Horiuchi M; Kondo T; Kaneko S; Fukushima Y. Is the predisposition to neuroleptic malignant syndrome genetically transmitted?. Br J Psychiatry. 1991; 158:850-3.
[13]  Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, Koshiro K, Otani K, Kaneko S. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet. 2003; 117B(1): 57.
[14]  Pope HG Jr, Aizley HG, Keck PE Jr, McElroy SL. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry. 1991; 52(5): 208.
[15]  Wu YF, Kan YS, Yang CH. Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report. Gen Hosp Psychiatry. 2011 May; 33(3): 301. e7-8. Epub 2011 Jan 8.
[16]  Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE, Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994; 182(3): 168.
[17]  Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989; 146(6): 717.
[18]  Hermesh H, Manor I, Shiloh R, Aizenberg D, Benjamini Y, Munitz H, Weizman A. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol. 2002; 22(3): 252.
[19]  Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry. 1998; 44(6): 499.
[20]  Boyer EW, Shannon M. N Engl J Med. 2005; 352(11): 1112. The serotonin syndrome.
[21]  Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ. 2003; 168(11): 1439.
[22]  Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology. 1995;45(2):219.
[23]  Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000; 79(4): 201.
[24]  Fleischhacker WW, Unterweger B, Kane JM, Hinterhuber H. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand. 1990; 81(1): 3.
[25]  Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry. 1989; 146(3): 324.
[26]  Julia Park, Josh Tan, Sylvia Krzeminski, Maryam Hazeghazam, Meghana Bandlamuri and Richard W. Carlson, Malignant Catatonia Warrants Early Psychiatric-Critical Care Collaborative Management: Two Cases and Literature Review, Case Reports in Critical Care, 2017, (1), (2017).
[27]  Caroff SN, Rosenberg H, Fletcher JE, Heiman-Patterson TD, Mann SC. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology. 1987;67(1):20.
[28]  Denborough M. Malignant hyperthermia. Lancet. 1998; 352(9134): 1131.
[29]  MacLennan DH, Phillips MS. Malignant hyperthermia. Science. 1992; 256(5058): 789.
[30]  Wappler F. Malignant hyperthermia. Eur J Anaesthesiol. 2001; 18(10): 632.
[31]  Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome. Ann Pharmacother. 2016; 50(11): 973.
[32]  Addonizio G, Susman VL. ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. J Clin Psychiatry. 1987 Mar; 48(3): 102-5.
[33]  Caroff SN, Mann SC, Keck PE Jr, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol. 2000; 20(2): 257.
[34]  Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999; 33(5): 650.
[35]  Davis JM, Janicak PG, Sakkas P, Gilmore C, Wang Z. Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome. Convuls Ther. 1991;7(2):111.
[36]  Morcos N, Rosinski A, Maixner DF. Electroconvulsive Therapy for Neuroleptic Malignant Syndrome: A Case Series. J ECT. 2019 Apr 22.
[37]  Harley JA, Peebles C, Porter RJ. Electroconvulsive therapy for catatonia secondary to neuroleptic malignant syndrome in a patient with multiple sclerosis. Aust N Z J Psychiatry. 2019 Jul; 53(7):703-704.
[38]  Gonz¨¢lez-Romero MF, Avina-Galindo AM, Elbe D, Friedlander R, Vila-Rodriguez F. Lifesaving Electroconvulsive Therapy for a Child With Autism Spectrum Disorder, Severe Self-Injurious Behavior, and Neuroleptic Malignant Syndrome. J ECT. 2019 Apr 22.
[39]  Tural U, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci. 2010 Feb; 64(1): 79-87.
[40]  Nakamura M, Yasunaga H, Miyata H, Shimada T, Horiguchi H, Matsuda S. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry. 2012; 73(4): 427.